The transplant diagnostics company turned fragments of donor DNA into a recurring-care business. A 2023 reimbursement shock forced a reset - and revealed a playbook built on narrow markets, repeat tests, and one very deep customer relationship.
ARNA Genomics US Inc. is a San Francisco-based biotechnology company developing multiomics liquid-biopsy technology for early cancer detection. Its lead assay, ARNA Breast, analyzes cell-free DNA and plasma enzyme activity from a routine blood draw to flag early-stage breast cancer, with proof-of-concept studies reporting sensitivity above 90%. Founded in 2013 and led by CEO Egor Melnikov, the company raised a $3.5M Series A in 2020 to fund clinical validation.